our Premium Content: News alerts, weekly reports and conference planners

GENE:

CD38 (CD38 Molecule)

News alerts, weekly reports and conference planners

CD38 overexpression drives glioblastoma progression via L1CAM/ICAM1/JAK-STAT-Driven tumor microenvironment rewiring. (PubMed, Transl Oncol)

CD38 overexpression in GBM drives tumor progression by amplifying immunosuppressive TME remodeling, positioning CD38 as a compelling target for further clinical investigation, supported by preliminary efficacy of daratumumab (NCT04922723) in patients with GBM.

3 days ago

Journal • IO biomarker

CD38 (CD38 Molecule) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • ICAM1 (Intercellular adhesion molecule 1) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • L1CAM (L1 cell adhesion molecule)

Darzalex (daratumumab)

Solitary extramedullary plasmacytoma of the tongue: a case report. (PubMed, Int J Surg Case Rep)

Currently, radiotherapy remains the cornerstone of treatment, providing excellent local control and durable long-term remission. This case underscores the exceptional rarity of primary extramedullary plasmacytoma of the tongue and highlights the effectiveness of radiotherapy as a curative and function-sparing treatment option for this condition, while emphasizing the necessity of long-term and lifelong surveillance to detect potential late recurrence or progression to multiple myeloma.

5 days ago

Journal

CD38 (CD38 Molecule) • SDC1 (Syndecan 1)

Unraveling the indolence of papillary thyroid carcinoma: an exploratory study on B-cell subsets based on genetic predisposition and tumor immunity. (PubMed, Front Immunol)

This study provides exploratory genetic and clinical evidence supporting a causal, protective role for specific peripheral and tumor-infiltrating B-cell subsets in PTC. Naïve B cells and CD27+ unswitched memory B cells are linked to indolent tumor behavior and favorable prognosis, highlighting their potential as biomarkers for risk stratification and non-invasive monitoring in PTC management.

8 days ago

Journal • IO biomarker

CD20 (Membrane Spanning 4-Domains A1) • CD38 (CD38 Molecule) • CD4 (CD4 Molecule) • CD27 (CD27 Molecule)

Phenotypic evolution of circulating plasma cells from early precursor stages to multiple myeloma. (PubMed, Haematologica)

Both BCMA and CD307e were more highly expressed on BM plasma-cells than CTPCs. This study is among the first to provide a comprehensive phenotypic characterisation of CD56+ CTPCs across the MM spectrum, including checkpoint and chemokine receptors, treated disease cases, and paired BM samples for NDMM.

9 days ago

Journal • PD(L)-1 Biomarker • IO biomarker

PD-1 (Programmed cell death 1) • CD38 (CD38 Molecule) • CD123 (Interleukin 3 Receptor Subunit Alpha) • IL2RA (Interleukin 2 receptor, alpha) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CD69 (CD69 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • SDC1 (Syndecan 1) • CCR7 (Chemokine (C-C motif) receptor 7) • CD14 (CD14 Molecule) • IL3RA (Interleukin 3 Receptor Subunit Alpha) • CCR6 (C-C Motif Chemokine Receptor 6) • HLA-C (Major Histocompatibility Complex, Class I, C) • ISG20 (Interferon Stimulated Exonuclease Gene 20)

10d

Analysis of ten cases of Acute lymphoblastic leukemia with non-KMT2A::AFF1 transcriptional variant 11q23 rearrangements (PubMed, Zhonghua Yi Xue Yi Chuan Xue Za Zhi)

The 11q23 rearrangement ALL with non-KMT2A::AFF1 transcript is mainly KMT2A::MLLT1, T-ALL is more common, and the rate of chromosomal karyotype detection is relatively low. Persistent positive KMT2A-r is unfavorable for patient survival, and allo-HSCT during the CR1 period may improve patient survival.

10 days ago

Retrospective data • Journal • IO biomarker

CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule) • CD8 (cluster of differentiation 8) • KMT2A (Lysine Methyltransferase 2A) • CD38 (CD38 Molecule) • WT1 (WT1 Transcription Factor) • CD22 (CD22 Molecule) • AFF1 (AF4/FMR2 Family Member 1) • CD34 (CD34 molecule) • CD5 (CD5 Molecule) • MME (Membrane Metalloendopeptidase) • CD7 (CD7 Molecule) • MLLT3 (MLLT3 Super Elongation Complex Subunit) • CD2 (CD2 Molecule) • AFDN (Afadin, Adherens Junction Formation Factor) • FUT4 (Fucosyltransferase 4) • MLLT10 (MLLT10 Histone Lysine Methyltransferase DOT1L Cofactor)

KMT2A rearrangement

10d

Nebivolol prevents exhausted T cells and enhances cytotoxicity against MCF-7 breast cancer cells in a β2-adrenergic receptor-dependent manner. (PubMed, Clin Exp Immunol)

These findings show that nebivolol reinvigorates CD4+ and CD8+ T cells following repeated activation, restoring their cytotoxic function against breast cancer cells in vitro. The immunomodulatory activity of Nebivolol is independent of β1-AR and mediated through β2-AR, suggesting that biased β₂-AR signaling may represent a potential strategy for modulating T cell exhaustion in the tumor microenvironment.

10 days ago

Journal • PD(L)-1 Biomarker • IO biomarker

CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD38 (CD38 Molecule) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD4 (CD4 Molecule) • ADRB2 (Adrenoceptor Beta 2) • CD2 (CD2 Molecule) • NFATC1 (Nuclear Factor Of Activated T Cells 1)

16d

Vitamin D receptor expression in germinal centre type diffuse large B-cell lymphoma cells is associated with vitamin D insensitivity. (PubMed, Endocr Oncol)

CD38 is also activated by VitD3 treatment of human peripheral B cell lines, where VDR can bind to the CD38 locus, suggesting direct regulation. Combined VDR and cell-of-origin assessment may contribute to a greater understanding of vitamin D's role in mature B-cell lymphoma and its interplay with BCL6 and MYC.

16 days ago

Journal • IO biomarker

MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL6 (B-cell CLL/lymphoma 6) • CD38 (CD38 Molecule) • VDR (Vitamin D Receptor)

Darzalex (daratumumab)

17d

Divergent CD27 expression marks the Treg induction trajectory. (PubMed, Front Immunol)

Our results define a population of induced Tregs in vitro and in vivo that is marked by elevated CD27 expression. Hence, CD27 expression may be useful to monitor therapeutic efficacy of Treg induction in vivo in clinical trials.

17 days ago

Journal • PD(L)-1 Biomarker • IO biomarker

PD-1 (Programmed cell death 1) • CD38 (CD38 Molecule) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CD70 (CD70 Molecule) • CD4 (CD4 Molecule) • CD27 (CD27 Molecule)

17d

Blastoid Mantle Cell Lymphoma in the Leukemic Phase: Resolving a Morphological Dilemma Through Flow Cytometry. (PubMed, Cureus)

Flow cytometric immunophenotyping demonstrated bright CD45 expression with low side scatter and positivity for CD19, CD20, CD38, CD5, CD79b, and FMC7 with negativity for CD34, CD23, CD200, and CD10, suggesting blastoid transformation of MCL rather than de novo ALL. This case highlights the critical role of flow cytometry in distinguishing blastoid MCL from acute leukemia, thereby preventing misdiagnosis and ensuring appropriate therapeutic decision-making.

17 days ago

Journal • IO biomarker

TP53 (Tumor protein P53) • CD20 (Membrane Spanning 4-Domains A1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • CD38 (CD38 Molecule) • CDK4 (Cyclin-dependent kinase 4) • CD79B (CD79b Molecule) • CD34 (CD34 molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CD5 (CD5 Molecule) • CD200 (CD200 Molecule) • MME (Membrane Metalloendopeptidase) • CDKN2C (Cyclin Dependent Kinase Inhibitor 2C) • FCER2 (Fc Fragment Of IgE Receptor II)

TP53 mutation • CD20 positive • CDKN2A deletion • RB1 deletion • PTPRC expression

22d

Absence of CD38 Expression in Mantle Cell Lymphoma Correlates with Distinct Pathological and Genetic Features. (PubMed, Hum Pathol)

Biologically, CD38-negative cnMCLs appear to be more likely driven by CD38-independent, alternative signaling pathways. From a clinical perspective, identification of CD38-negative cnMCLs by flow cytometry may help recognizing patients at increased risk for adverse genetic features, including TP53 inactivation.

22 days ago

Journal • IO biomarker

TP53 (Tumor protein P53) • NOTCH1 (Notch 1) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • IGH (Immunoglobulin Heavy Locus) • KMT2D (Lysine Methyltransferase 2D) • CD38 (CD38 Molecule) • CD79B (CD79b Molecule) • NOTCH2 (Notch 2) • SOX11 (SRY-Box Transcription Factor 11) • NSD2 (Nuclear Receptor Binding SET Domain Protein 2)

TP53 mutation • ATM mutation • IGH mutation

ULK4 and CDKN2A polymorphisms influence the risk of developing monoclonal gammopathy of undetermined significance. (PubMed, Int J Cancer)

Additionally, the CDKN2Ars2811710 variant showed a suggestive association with MGUS risk (p = 2.17 × 10-4), affecting transcription factor binding involved in B-cell proliferation and differentiation, although it lacked association with immune markers. In conclusion, we confirm a genome-wide significant association of the ULK4 locus and MGUS risk, supporting its role in early B-cell differentiation, and identify CDKN2A as a candidate susceptibility locus warranting further investigation.

1 month ago

Journal • IO biomarker

CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CD38 (CD38 Molecule) • CD24 (CD24 Molecule) • CD27 (CD27 Molecule) • ULK4 (Unc-51 Like Kinase 4)

Anaplastic Lymphoma Kinase (ALK)-Positive Large B-cell Lymphoma in Children: A Case Report and Review of Literature. (PubMed, Cureus)

The patient was treated with CHOP chemotherapy, with alectinib added from the second cycle...Notably, neuron-specific enolase levels increased in parallel with disease progression. This case highlights diagnostic challenges related to an unusual clinical presentation and pathological overlap with other hematologic diseases.

1 month ago

Journal • IO biomarker

ALK (Anaplastic lymphoma kinase) • CD38 (CD38 Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • IRF4 (Interferon regulatory factor 4)

ALK positive • ALK mutation • PTPRC expression

Alecensa (alectinib)